2 products found
Ascelia Pharma AB Products
-
Pipeline
Our Phase III lead candidate Mangoral is a liver imaging drug (i.e. a liver specific contrast agent) being developed for detection and localization of potential liver metastases, using Magnetic Resonance Imaging (“MRI”) in patients where use of the current gold standard gadolinium-based contrast agents (“GBCAs”) may be medically inadvisable or cannot be administered. Mangoral is in Phase III clinical development. Our second drug candidate Oncoral is a novel tablet-based formulation of the well-known chemotherapeutic agent irinotecan, intended for the treatment of advanced gastric (stomach) cancer. Irinotecan is today mainly used for treating metastasized colorectal cancer. Although irinotecan is currently not approved for treating gastric cancer in the United States and in the EU, there is off-label use for this indication. Oncoral has completed Phase I of clinical studies with promising results and is now being prepared for Phase II clinical studies.
-
Orviglance - MR-Imaging of the Liver
Mangoral is a novel oral imaging agent in development for use in MR-imaging of the liver. Mangoral aims to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with severe kidney impairment. Mangoral is currently in Phase 3 development including the registration-enabling study, ...
-
Oncoral - Novel Daily Irinotecan Chemotherapy Agent
Oncoral is a novel daily irinotecan chemotherapy in development. Irinotecan chemotherapy has an established potent anti-tumor effect – even in difficult to treat cancers. Oncoral is a daily irinotecan tablet with the potential to offer better patient outcomes with improved safety following the daily dosing at home compared to intravenous high-dose infusions at the hospital. Following successful Phase 1 results, Phase 2 clinical development for ...